Ind-Swift Laboratories' Punjab unit commissionedIllustrative image – not actual.

Ind-Swift Laboratories Ltd (ISLL) has begun commercial production at its new multi-purpose plant at Dera Bassi in Punjab. The plant would be manufacturing four specialty bulk drugs– Pioglitazone, Candesartan, Ramipril and Clopidogrel.

 

The unit has been set up at a cost of Rs.6 crore comprising Rs.4 crore of term loans and Rs.2 crore of internal accruals.

 

ISLL, a Chandigarh-based company engaged in the manufacture of bulk drugs and intermediaries, is part of the Rs.150 crore Ind-Swift group.

← All latest storiesBack to top →